Transforming Lifetimes through seed-stage venture investing in pediatric-focused companies
Our team’s background is uniquely suited to the diverse demands of this venture, and includes executive experience at companies ranging from seed-stage startups to the Fortune 500, in philanthropy, in academia at leading medical centers and in venture capital. We have a well-curated network for deal sourcing, due diligence, and post-investment venture growth. We are headquartered in the San Francisco Bay Area, California, with members of our advisory team spanning leading medical research institutes around the US.
Children make up 24% of the population in the US and represent over $700B in healthcare spend, yet there are many areas of high unmet need. Millions of children in America, including the 20 million with rare diseases, still lack solutions to their medical needs. They either experience poor quality of life or die at a young age.
A regulatory shift in federal policy through acts like the Orphan Drug Act, BPCA[1] and PREA[2] is creating incentives for new solutions for diseases that affect children.
Scientific breakthroughs such as gene & cell therapies, technology-driven drug discovery and drug repurposing make it possible to treat previously untreatable diseases that disproportionately affect children.
Trends like wearables, digital health apps, reduced sequencing costs, digitized biological data, and AI & Deep Learning in drug discovery are solving previously intractable healthcare problems.
Only 9-12% of the NIH budget is allocated to pediatric medical research. Further, the private sector focus on large markets has prevented many important pediatric discoveries from being commercialized.
Addressing the funding gap will bring to market many promising therapies with significant impact on pediatric health.
Interested in partnering with us? Share your details below, and let’s explore opportunities to transform lives through pediatric-focused investments together!
